#COVID19 Vaccine-Maker Shuts Global Plants After Cyber-Attack

#COVID19 Vaccine-Maker Shuts Global Plants After Cyber-Attack

An Indian pharmaceutical giant has been forced to shut operations at several global facilities after suffering an unspecified cyber-attack.

360 Mobile Vision - 360mobilevision.com North & South Carolina Security products and Systems Installations for Commercial and Residential - $55 Hourly Rate. ACCESS CONTROL, INTRUSION ALARM, ACCESS CONTROLLED GATES, INTERCOMS AND CCTV INSTALL OR REPAIR 360 Mobile Vision - 360mobilevision.com is committed to excellence in every aspect of our business. We uphold a standard of integrity bound by fairness, honesty and personal responsibility. Our distinction is the quality of service we bring to our customers. Accurate knowledge of our trade combined with ability is what makes us true professionals. Above all, we are watchful of our customers interests, and make their concerns the basis of our business.

Dr Reddy’s, which produces COVID-19 treatments remdesivir and favipiravir and has just signed a deal to manufacture Russia’s Sputnik-V vaccine, saw shares plummet by over 4% following the announcement.

A statement from CIO Mukesh Rathi sought to calm investors after the news was first reported on Indian channel ET Now.

“We are anticipating all services to be up within 24 hours and we do not foresee any major impact on our operations due to this incident,” he reportedly said in a statement.

There’s little publicly available information on the attack, except that the pharma giant has been forced to “isolate” all of its data centers and shut down plants in the United States, UK, Brazil, India and Russia.

It’s therefore unclear whether the intent of the attackers was to spread ransomware, steal data, or both.

Bill Conner, UK government advisor and CEO of SonicWall, argued that research and pharmaceutical facilities are home to some of the most valuable IP in the world today.

“If seized, it could grant a significant advantage to the party who holds it, and indeed catapult a whole economy,” he added. “Given this, whoever holds this research can claim a high price for it. Hostile actors who wish to influence or control global healthcare at this time of great need, to gain either monetary or geopolitical advantage, will be willing to pay this bounty.”

The Hyderabad-headquartered firm, which also produces medicines for the NHS, announced last week that it had received approval from the Drugs Controller General of India to begin an adaptive phase 2/3 human clinical trial for Sputnik-V in India.

By admin